Guidelines

First-ever gestational trophoblastic neoplasia guidelines published


 

Reassuring insurers

Dr. Mutch said that he and his colleagues in GTN centers sometimes treat patients with intermediate or high-risk disease who were started on single-agent therapy or suboptimal therapies and present with advanced, drug-resistant disease.

“These guidelines were established so that people could see exactly what needs to be done when,” he said.

The guidelines also are critical for convincing third-party payers about the need for specific treatments, he added.

“I had a high-risk patient who needed EMA/CO, and the insurance company said ‘well, there’s no NCCN guidelines – we won’t approve it.’ So then I had to wait 3 days while it went through peer review. Meanwhile, the tumor doubled in size, and then the nurse who was reviewing it declined the ‘CO’ part, so that was delayed a week, and it really jeopardized this patient’s survival,” Dr. Mutch said.

The guidelines also include recommendations for patients with special clinical situations, such as women with clinical responses to EMA/CO who continue to have plateauing low levels of hCG or have a re-elevation of hCG levels after having a complete response to EMA/CO.

There are also specific recommendations for treatment of two even rarer intermediate trophoblastic tumor types: placental-site trophoblastic tumor and epithelioid trophoblastic tumor.

The guidelines are supported by the NCCN. Dr. Mutch reported consulting/advisory board participation for Clovis. Dr. Horowitz reported having no relationships to disclose.

SOURCE: Gestational Trophoblastic Neoplasia. NCCN.org, Version 1.2019, published Aug. 9, 2018.

Pages

Recommended Reading

A new way to classify endometrial cancer
MDedge Hematology and Oncology
FDA approves pembrolizumab for cervical cancer
MDedge Hematology and Oncology
FDA approves bevacizumab for advanced ovarian cancer
MDedge Hematology and Oncology
SLN mapping is most cost-effective in low-risk endometrial carcinoma
MDedge Hematology and Oncology
Intensive nonaspirin NSAID use linked to reduced ovarian cancer mortality
MDedge Hematology and Oncology
IVF linked to slight increase in risk of some cancers
MDedge Hematology and Oncology
ACA coverage mandate leads to more insurance for young women, early gynecologic cancer diagnoses
MDedge Hematology and Oncology
PARP inhibitors didn’t impair QOL as ovarian cancer maintenance therapy
MDedge Hematology and Oncology
Phase 2 trial: Dendritic cell vaccine maintenance prolongs PFS in EOC
MDedge Hematology and Oncology
VEGF inhibitor shows promise in platinum resistant/refractory ovarian cancer
MDedge Hematology and Oncology